Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

Velcade image

NICE approves Velcade

March 21, 2014
Sales and Marketing Janssen, NHS, NICE, Velcade, myeloma

NICE has recommended Janssen’s proteasome inhibitor Velcade as an induction treatment for some patients with newly-diagnosed multiple myeloma. The draft …

News
EMA image

EMA launches speedy pilot

March 21, 2014
Sales and Marketing BIA, EMA, MHRA, NICE, early access, trials

The European Medicines Agency (EMA) has launched an initiative aimed at speeding up the drug approval process and wants help …

News

Boehringer’s first cancer drug gains NICE yes

March 17, 2014
Sales and Marketing Boehringer, Cancer, NICE, NSCLC, afatinib, giotrif

NICE is recommending that Boehringer Ingelheim’s first oncology treatment Giotrif be funded by the NHS. The new final draft guidance …

News
Inlyta image

NICE U-turn on Pfizer drug Inlyta

March 5, 2014
Research and Development, Sales and Marketing Kidney cancer, NHS, NICE, Pfizer, axitinib, inlyta

NICE has recommended that Pfizer’s kidney cancer drug Inlyta should be used for some patients in England, following a similar …

News
Soliris image

Alexion ‘concerned’ over NICE draft

March 4, 2014
Sales and Marketing NICE, aHUS, alexia, blood, eculizumab, soliris

Alexion Pharmaceuticals UK has expressed ‘concern’ that NICE has not yet allowed its rare disease treatment Soliris to be formally …

News
GSK sign

GSK submits new Promacta licence

March 3, 2014
Sales and Marketing GSK, NICE, Promacta, Revolade, blood, eltrombopag

GlaxoSmithKline is seeking a new licence for its blood disorder drug Promacta in patients with severe aplastic anaemia. Specifically, the …

News
Alimta image

NICE rejects Alimta

February 28, 2014
Sales and Marketing Alimta, Cancer, NHS, NICE, NSCLC, lilly, pemetrexed

Eli Lilly is coming to terms with rejection by NICE after the cost watchdog said it would not recommend Alimta …

News
Yervoy image

NICE restricts Yervoy use

February 25, 2014
Sales and Marketing BMS, Cancer, NHS, NICE, Yervoy, melanoma

Bristol-Myers Squibb has been dealt a blow by NICE after the UK cost watchdog recommended that the use of skin …

News
Lisa image

A treatment room view

February 24, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDF, Cancer, NHS, NICE, Roche, avastin, hinsely

A little more than a year ago, Lisa Hinsley’s prospects were not good. The mother of three had been diagnosed …

Feature
Germany flag

German law could see pharma discounts published

February 18, 2014
Sales and Marketing AMNOG, Germany, IMS, NICE, prices

Pharma companies are apprehensive about German lawmakers opening Pandora’s Box this week if they go ahead with plans to publish …

News

NICE: new system will allow more drugs on NHS

February 17, 2014
Sales and Marketing DH, Dillon, DoH, NHS, NICE, QALY

NICE has said that it will be able to approve more medicines under a new drug pricing policy, but warns …

News
Germany image

Germany focus: strength with control

February 17, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AMNOG, EFPIA, Germany, IQWIG, NHS, NICE

Germany is the biggest pharmaceutical market in Europe and one of the biggest in the world, but new systems and …

Feature
NICE image

NICE: ‘Use more statins’

February 12, 2014
Sales and Marketing NHS, NICE, baker, cvd, statins

NICE has decided more NHS patients ought to be considered at risk of cardiovascular disease (CVD) – and therefore advises …

News
sir michael parkinson image

Sir Michael Parkinson criticises NICE

February 4, 2014
Medical Communications, Sales and Marketing Astellas, NHS, NICE, Xtandi, parkinson, prostate

TV host Sir Michael Parkinson has told NICE that it must lift the restrictions imposed on Astellas’ new prostate cancer …

News
Roche image

Roche: NICE guidance ‘perverse’

February 4, 2014
Sales and Marketing NHS, NICE, NSCLC, Roche, Tarceva

Roche has poured scorn on NICE’s ‘perverse’ recommendation that its EGFR-TK inhibitor Tarceva should no longer be given to NHS …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026